Management of anemia in patients with cancer

被引：13

作者：

Steensma D.P. ^{[1
]}

机构：

[1] Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905

来源：

Current Oncology Reports | 2004年 / 6卷 / 4期

关键词：

Erythropoietin; Darbepoetin Alfa; Intravenous Iron; Iron Sucrose; Iron Dextran;

D O I：

10.1007/s11912-004-0039-9

中图分类号：

学科分类号：

摘要：

Anemia is extremely common in patients with cancer. Low hemoglobin levels are associated with diminished quality of life and possibly decreased overall survival. Successful treatment of anemia has undeniable benefits for patients, often yielding dramatic symptomatic improvement that can be very satisfying for clinicians to observe. This review focuses on evolving issues in the management of anemia in patients suffering from cancer. Topics addressed include new evidence-based guidelines concerning the use of epoetin alfa, the evolving role of darbepoetin alfa in cancer-associated anemia, the potential for concomitant iron supplementation to maximize response to erythropoietic agents, the unresolved question of whether erythropoietin use affects survival in cancer patients, new concerns about the risk of thromboembolism in cancer patients with higher hemoglobin levels who are receiving epoetin, and possible immunosuppressive effects of blood product transfusions that may have relevance to neoplasia progression. Copyright © 2004 by Current Science Inc.

引用

页码：297 / 304

页数：7

共 54 条

[1]

Coiffier B., Guastalla J.P., Pujade-Lauraine E., Bastit P., Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy results of a retrospective survey, Eur. J. Cancer, 37, pp. 1617-1623, (2001)

[2]

Spivak J.L., Cancer-related anemia: Its causes and characteristics, Semin. Oncol., 21 SUPPL. 3, pp. 3-8, (1994)

[3]

Miller C.B., Jones R.J., Piantadosi S., Et al., Decreased erythropoietin response in patients with the anemia of cancer, N. Engl. J. Med., 322, pp. 1689-1692, (1990)

[4]

Cella D., Factors influencing quality of life in cancer patients: Anemia and fatigue, Semin. Oncol., 25 SUPPL. 7, pp. 43-46, (1998)

[5]

Vogelzang N.J., Breitbard W., Cella D., Et al., Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition, Semin. Hematol., 34, SUPPL. 2, pp. 4-12, (1997)

[6]

Rizzo J.D., Lichtin A.E., Woolf S.H., Et al., Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology, Blood, 100, pp. 2303-2320, (2002)

[7]

Uses of Epoetin for Anemia in Oncology, (2001)

[8]

Henry D.H., Guidelines for the use of epoetin in cancer patients: A much-needed step forward in standardizing anemia treatment, Blood, 102, pp. 2697-2698, (2003)

[9]

Patrick D.L., Gagnon D.D., Zagari M.J., Et al., Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa, Eur. J. Cancer, 39, pp. 335-345, (2003)

[10]

Cella D., Zagari M.J., Vandoros C., Et al., Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population, J. Clin. Oncol., 21, pp. 366-373, (2003)

← 1 2 3 4 5 6 →